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Objectives: To characterise and document the progression of idiopathic renal haematuria in a large 
 cohort of medically managed UK dogs.
Materials and MethOds: Retrospective study of 41 client-owned dogs with confirmed (n=14), or 
 suspected (n=27) idiopathic renal haematuria from 4 UK-based referral centres. Clinical findings and 
outcomes of dogs (2001 to 2018) were determined from the review of medical records and telephone 
follow-up.
results: Median survival time from diagnosis was long [1482 (152 to 1825) days] irrespective of 
treatment and clinical response. Only 1 case was euthanased due to idiopathic renal  haematuria, 
and anaemia or azotaemia occurred infrequently. In total, 25 dogs received angiotensin-converting 
 enzyme-inhibitor or angiotensin receptor blocker therapy, of which 23 received benazepril [0.44 
(0.19 to 0.82) mg/kg/24 hours], two received enalapril (0.40 and 0.78 mg/kg/24 hours) and one 
received telmisartan (1 mg/kg/24 hours). In cases with follow-up urinalyses, complete  resolution 
of  haematuria was documented in eight of 19 (42%) dogs following angiotensin-converting 
 enzyme-inhibitor/ angiotensin receptor blocker treatment, with partial improvement in five of 19 (26%) 
and no  improvement in six of 19 (31%). Conversely, of the two untreated dogs where outcome was 
available, one had partial improvement and the other had no improvement.
clinical significance: In this study, idiopathic renal haematuria was associated with a good  
prognosis and low complication rate. Resolution or improvement in haematuria occurred in both 
angiotensin-converting enzyme-inhibitor/angiotensin receptor blocker-treated and untreated dogs, 
indicating that further studies are required to evaluate the effectiveness and safety of these  
interventions.
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INTRODUCTION
Idiopathic renal haematuria (IRH), or benign essential haema-
turia, is a rare cause of chronic and potentially severe blood loss. 
In both dogs and humans, it has been previously been defined as 
acute, intermittent, or chronic gross haematuria for which radio-
logic and haematologic evaluation reveals no source (Bagley & 
Allen 1990; Tawfiek & Bagley 1998; Berent et al. 2013; Berent 
& Weisse 2014). Therefore, diagnosis typically relies on exclu-
sion of alternative aetiologies including trauma, urolithiasis, neo-
plasia, coagulopathy and urinary tract infection. Confirmation 
of upper urinary tract haemorrhage has historically necessitated 
surgically assisted ureteral catheterisation; however, the increased 
availability of cystoscopy has permitted minimally invasive 
confirmation and more definitive exclusion of urethral lesions 
(Stone et al. 1983, Holt et al. 1987, Berent et al. 2013, Berent & 
Weisse 2014, Adelman et al. 2017).
The cause of IRH in dogs remains poorly understood. In 
humans, haemorrhage is often attributed to vascular abnormali-
ties, such as haemangiomas and angiomas of the renal papillae 
or pelvis (Rowbotham & Anson 2002, Dooley & Pietrow 2004, 
Tanimoto et al. 2017); however, in the largest study describing 
renal histopathology in IRH-affected dogs, this was confirmed 
in only one of nine cases, with the remaining eight cases having 
no clear aetiology (Holt et al. 1987). The advent of ureteropy-
eloscopy has recently led to the documentation of renal pelvic 
lesions with an appearance suggestive of angiomas in several dogs 
with IRH; however, their true prevalence in this species remains 
unknown and other aetiologies are potentially also possible (Taw-
fiek & Bagley 1998, Dooley & Pietrow 2004, Araki et al. 2012, 
Berent & Weisse 2014). In humans, haematuria is often related 
to glomerular disease (including IgA nephropathy, Alport syn-
drome and thin basement membrane disease), accounting for 
up to 66% of cases, and similar syndromes may therefore also 
exist in the dog (Kupor et al. 1975, Chester et al. 1978, Fairley 
& Birch 1982, Tapp et al. 1986, Rowbotham & Anson 2002, 
Yuste et al. 2015). Although glomerular haematuria is reportedly 
uncommon in dogs, this assumption is based on supposition 
rather than evidence. Abnormal urinary erythrocyte morphology 
and compatible renal histopathology often facilitate its diagnosis 
in people; however, this information in rarely available for dogs 
and interpretation of proteinuria is complicated by the coexis-
tence of urinary haemorrhage (Fairley & Birch 1982, Yuste et al. 
2015).
Due to the risk of anaemia, iron deficiency and ureteral or ure-
thral obstruction, ureteronephrectomy was historically recom-
mended for dogs with IRH (Stone et al. 1983, Hitt et al. 1985, 
Holt et al. 1987, Jennings et al. 1992, Hawthorne et al. 1998). 
Given the inevitable detriment to renal function and the high 
incidence of subsequent bilateral disease however, various other 
options have been investigated (Mishina et al. 1997, Berent et al. 
2013, Di Cicco et al. 2013, Berent & Weisse 2014, Adelman 
et al. 2017). Most recently, two studies described the treatment 
of IRH with endoscopically assisted sclerotherapy (Berent et al. 
2013, Adelman et al. 2017). Although this resolved gross hae-
maturia in six of eight cases, this procedure requires specialist 
equipment, training and expertise, and is not widely available. 
Furthermore, although uncommon, renal pain has been reported 
in both humans and dogs following sclerotherapy, and other com-
plications including vomiting, corrosive renal and ureteral injury, 
and renal dysfunction may potentially also occur (Goel et al. 
2004, Berent et al. 2013). Interestingly, in the aforementioned 
study by Berent et al., ureteropyeloscopy was performed in one 
of the two persistently haematuric dogs but failed to document 
a bleeding lesion, supporting the theory that other aetiologies 
may result in renal haematuria and have indistinguishable clinical 
signs (Berent et al. 2013).
Angiotensin-converting enzyme inhibitors (ACEi) and angio-
tensin receptor antagonists (ARBs) are commonly used for the 
management of glomerular proteinuria, acting by preferential 
dilation of the efferent glomerular arteriole and consequent 
reduction in intraglomerular pressure (Grauer et al. 2000, Brown 
et al. 2013). In addition, complex roles of angiotensin in the reg-
ulation of renal hemodynamics and medullary blood flow, and 
glomerular permselectivity have also been suggested (Chou et al. 
1986, Cupples et al. 1988, Borchhardt et al. 1997, Ba̧dzyńska 
et al. 2002, Sangalli et al. 2011). In humans, ACEi may be rec-
ommended for certain forms of renal haematuria (Hebert et al. 
1996, Tojo et al. 2006, Kashtan et al. 2013). Given that the aeti-
ology of IRH in dogs is poorly understood and no previous stud-
ies have investigated medical treatment options, the aim of this 
study was to better characterise the disease in a large number of 
conservatively managed dogs with confirmed or suspected IRH 
and to evaluate whether ACEi/ARB therapy is associated with 
improvement of haematuria.
METHODS
Hospital records from four UK-based veterinary referral institu-
tions (one university and three private practices) were each retro-
spectively searched for cases with a final diagnosis of IRH. Searches 
and assessment of case eligibility were performed independently 
by a single operator from each institution (AJK, JB, ACCK, AGS, 
respectively). Clinical information regarding signalment, histori-
cal findings, previous treatment, physical examination findings, 
results of diagnostic investigations and treatment recommenda-
tions were derived from each case’s medical records by each of 
the aforementioned operators and subsequently submitted as an 
anonymised Microsoft Excel spreadsheet to the primary investiga-
tor (AK) for collation and analysis. All diagnoses were made by a 
European or American board-certified specialist in small animal 
internal medicine following thorough diagnostic investigation 
performed at the discretion of the primary clinician. Decisions 
regarding treatment, including the type, dose and frequency of 
ACEi or ARB therapy, were dictated by clinician preference. Min-
imum inclusion criteria comprised persistent haematuria in the 
absence of an alternative underlying aetiology based on a com-
bination of: clinical history, physical examination, haematology, 
serum biochemistry, complete urinalysis, urine culture, coagula-
tion profile and abdominal imaging (including ultrasonography, 
radiography, intravenous urography, urethrocystography).
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Cases were further divided into two subpopulations: those 
with confirmation of haemorrhage from the ureterovesicular 
junction (UVJ) (Group IRH-C); and those where renal haemor-
rhage was suspected based on exclusion other aetiologies (Group 
IRH-S). Cases with incomplete medical records, abnormalities 
on diagnostic evaluation suggestive of another possible aetiology 
for haematuria, or evidence of concurrent disease were excluded.
For each case meeting the inclusion criteria, follow-up data 
were obtained by contacting referring veterinary practices in 
order to determine response following treatment. Improvement 
of haematuria was defined as: “complete resolution” if subse-
quent urinalysis demonstrated resolution of macroscopic and 
microscopic haematuria; “partial improvement” if treatment 
was associated with reduction in the severity of gross haematuria 
but persistence of microscopic haematuria on repeat urinalysis; 
or “no improvement” if the magnitude of haematuria was con-
sidered unchanged. Details of adverse effects relating to ACEi 
treatment or disease progression, and results of subsequent clini-
copathological investigations (haematology, biochemistry, urinal-
ysis) were also recorded. Relapses of haematuria, either recorded 
on subsequent urinalyses or due to re-presentation for recurrence 
of gross haematuria, were also recorded.
Statistical analysis
Data analysis was performed on the entire data set (i.e. 
IRH-S + IRH-C) followed by sub-analysis of Groups IRH-C 
and IRH-S alone. Descriptive statistics were used to describe 
the signalment, clinical signs, clinicopathological and diagnostic 
imaging findings of the dogs with IRH, and to evaluate longi-
tudinal progression of the disease and response following treat-
ment. Survival time was defined as the time between diagnosis 
of IRH and death or euthanasia (all-cause mortality) and was 
investigated using Kaplan–Meier analysis. Survival times were 
compared between groups using the Log-rank test. Dogs that 
were alive or lost to follow up at the study end-point (December 
2018) were censored from the survival analysis. Due to the low 
numbers of dogs per treatment and diagnosis group, and con-
sequently low statistical power, further subgroup analyses were 
not performed.
Statistical analysis was performed using commercially avail-
able software (IBM SPSS Statistics v25 for Windows, IBM 
Corp, Armonk, New York and GraphPad Prism v6 for Windows, 
GraphPad Software, La Jolla, California) and P < 0.05 was con-
sidered statistically significant. Unless otherwise stated, data are 
presented as median (range), or number (percentage).
RESULTS
Patient population
In total, 41 dogs met the criteria for inclusion (2001 to 2018). 
Case selection, pertinent clinical data and outcomes are sum-
marised in Fig 1 and Table 1. In total, 20 different breeds were 
represented, of which the most common were: cocker spaniels 
(seven cases), boxers (six cases) and Labrador retrievers (three 
cases). The median age was 4.5 years (3 months to 13.25 years). 
There were 24 male dogs (15 neutered, nine entire) and 17 
females (11 neutered, six entire).
Gross haematuria was the primary presenting sign in 39 cases 
(95.1%), whereas haematuria was identified incidentally in two 
dogs (4.9%). Intermittent dysuria, attributed to voiding of blood 
clots, was additionally reported in four dogs (9.7%; two IRH-C 
and two IRH-S). Overall, 33 dogs had received treatment before 
referral following the onset of haematuria but with no significant 
improvement (Table S1). Clinical examination performed at the 
time of referral was unremarkable in all dogs, other than mild 
hyperthermia in one case (39.2°C), and blood pressure measure-
ment was <160 mmHg or reported as within normal limits in the 
11 cases where this information was available.
Clinicopathological findings
Haematology and biochemistry results were available for review 
in 37 of 41 and 36 of 41 cases, respectively, with no significant 
abnormalities reported in the remaining dogs. Median packed 
cell volume (PCV) or haematocrit (HCT) was 45% (21 to 59%) 
with eight of 41 dogs reported to have a mild or moderate anae-
mia (PCV/HCT 21 to 34%). This was considered to be regen-
erative in three cases, non-regenerative in two cases (all samples 
obtained >1 week after onset of haematuria), and was not speci-
fied in three cases. Microcytosis and hypochromasia, suggestive 
of iron deficiency, was documented in two dogs with moderate, 
non-regenerative anaemia (PCV/HCTs of 21 and 26%; one 
IRH-C and one IRH-S); however, serum iron quantification was 
not performed. Both cases had a chronic history of gross haema-
turia over the preceding 6 months.
Automated platelet counts were variable, ranging from 
122×109/L to 543×109/L (median 273×109/L). Mild thrombo-
cytopaenia was reported in four dogs but was not considered to 
be of sufficient severity to result in spontaneous haemorrhage. 
Prothrombin and activated partial thromboplastin times were 
recorded in 29 cases, buccal mucosal bleeding times in three, 
d-dimers concentration in three, von Willebrand’s factor antigen 
concentration in two and Angiostrongylus vasorum serology in one 
case – all were considered within normal limits. Thromboelastog-
raphy was performed in five cases and was reported as unremark-
able in three and suggestive of mild hypercoagulability in two 
likely reflecting in vitro artefact due to anaemia.
Azotaemia, defined as an increase in serum urea or creatinine 
concentration exceeding the laboratory reference intervals, was 
generally uncommon although mild elevations in serum creat-
inine were noted in two dogs (140 and 182 μmol/L). In both 
cases, urine-specific gravity was sub-optimally concentrated, 
suggestive of a renal or post-renal origin. Other derangements 
in biochemical parameters were generally mild and non-specific 
(Table S2).
Urinalysis results were available for review in 36 dogs and 
reported as unremarkable, aside from haematuria, in the remain-
ing five. A strongly positive heme reaction (4+) on dipstick 
evaluation and >50 erythrocytes per high power field (hpf ) on 
sediment examination was documented in all samples and 72% 
(26/36) were noted to have red/brown discolouration. Median 
urine-specific gravity was 1.032 (1.010 to 1.050). All but one 
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dog had concurrent proteinuria on dipstick evaluation (1+ to 3+) 
with urine protein: creatinine ratios (UPC) ranging from 0.20 
to 17.4 (median 1.50, n=27). Other than marked haematuria, 
analysis of urinary sediment was largely unremarkable except 
for occasional struvite crystals in three cases, rare granular casts 
in two cases and granular debris in one case. Pyuria was docu-
mented in only four dogs (median 25 cells/hpf; range: 20 to 90 
cells/hpf ) and bacterial culture results were negative in all cases.
Diagnostic imaging and endoscopic findings
Abdominal imaging was performed in all dogs, including abdom-
inal ultrasound in 41 cases, radiography in 25, MRI in three and 
CT in two. Contrast imaging was undertaken in 24 dogs, includ-
ing intravenous urography in 15 cases and retrograde urethrocys-
tography in nine. Pyelectasia or ureteral dilation was documented 
in 10 cases with suspected blood clots within the renal pelvis or 
ureters in six dogs. In addition, structures consistent with clots 
within the urinary bladder were described in five dogs (three 
with concurrent renal or ureteral clots), and echogenic sediment 
within the urinary bladder was reported in a further 10 cases. 
Other than occasional small (<1 cm), thin walled, anechoic cysts 
within the renal parenchyma in three dogs, no other structural 
abnormalities were described.
Cystoscopy was performed in 17 dogs and haemorrhage from 
the UVJ was visualised in 11 cases. In the remaining six dogs, 
the ureteral jets were subjectively normal in appearance; however, 
the degree of haematuria at the time of cystoscopy was milder 
than at initial presentation and no other causative lesions were 
identified. IRH was therefore suspected, however ureteral cath-
eterisation or repeat cystoscopy was not performed to confirm 
the diagnosis. In addition to those undergoing cystoscopy, upper 
urinary tract haemorrhage was also confirmed in three dogs by 
exploratory laparotomy and cystotomy. Overall, of the 14 dogs 
where gross haematuria from the UVJ was visualised, haemor-
rhage was unilateral in 11 (left-sided in five dogs, right-sided in 
four and unspecified in two), and bilateral in three dogs. No con-
current structural abnormalities or developmental malformations 
were reported in any cases.
Treatment
Twenty-five dogs were treated with an ACEi or ARB, 14 received 
no specific treatment and two dogs underwent unilateral 
FIG 1. Flowchart illustrating case selection, subcategorisation, and outcomes following treatment. The study population was divided into cases with 
confirmed (Group IRH-C) or suspected (Group IRH-S) and further subdivided according to treatment. In cases where repeat urinalyses were available, 
change in haematuria was described as either complete resolution (CR), partial improvement (PI) or no improvement (NI). Outcomes for groups IRH-C, 
IRH-S and the overall study population are detailed at the bottom of the flowchart. The number of cases in each group that were excluded from the 
follow-up analysis, along with reasons for the exclusion, are also specified
ACEi and ARBs in idiopathic renal haematuria
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nephrectomy. Treatment with benazepril was recommended in 
23 of 25 cases [median 0.44 mg/kg/24 hours (0.19 to 0.82 mg/
kg/24 hours)] and enalapril in two dogs (0.40 and 0.78 mg/
kg/24 hours, respectively). In one dog, treatment was initiated 
with benazepril but subsequently continued with telmisartan 
(1 mg/kg/24 hours). Indefinite treatment was recommended in 
seven cases, whereas treatment was discontinued after a median of 
7.4 months (0.75 to 52 months) in the remaining 14 dogs where 
this information was available. In addition, 18 dogs concurrently 
received other therapies, including symptomatic treatments and 
antibiosis (Table S3); however, none received anti-androgen ther-
apy or underwent castration.
Outcome and survival analysis
Follow-up haematology [152 (9 to 1879) days following diag-
nosis], and serum biochemistry analyses [38 (9 to 1878) days 
following diagnosis] were available in 15 cases, of which 13 had 
received ACEi/ARBs and two received no specific treatment. 
No adverse effects of ACEi/ARB treatment, such as elevation 
in creatinine, electrolytes abnormalities, gastrointestinal signs or 
incoordination/weakness, were documented. Irrespective of the 
severity of initial clinical signs or disease progression, no dogs 
developed azotaemia or sustained a deterioration in creatinine 
and only one patient (Group IRH-S) remained anaemic on 
repeat haematology analysis with PCV/HCT in the other cases 
remaining within normal limits. This dog was severely haematu-
ric with a hypochromic non-regenerative anaemia (PCV/HCT 
21%) on initial presentation, responded poorly to benazepril and 
tranexamic acid therapy, and was euthanased 150 days following 
diagnosis due to persistent haematuria and anaemia (PCV/HCT 
of 20%).
Response following treatment could be determined for 21 dogs 
(Fig 1), with results of one or more subsequent urinalyses [72 (6 
to 1878) days following diagnosis] available in 19 cases, and two 
reported to have persistent, unchanged gross haematuria. Over-
all, of dogs receiving ACEi/ARB treatment (n=19), eight (42%) 
were considered to have complete resolution of both macroscopic 
and microscopic haematuria. Partial improvement occurred in 
five dogs (26%), and six (32%) had no improvement following 
treatment. Both dogs which additionally received tranexamic 
acid had either partial or no improvement. Of the dogs receiv-
ing no specific treatment (n=2), one had partial improvement 
and the other had no improvement. Due to the small number of 
untreated dogs and consequent lack of statistical power, further 
statistical analysis of these data was not performed.
Of the 14 dogs with complete resolution or partial improve-
ment, only three were re-presented to their primary or referral 
veterinarian for recurrence or worsening of haematuria: two of 
these dogs had received ACEi/ARB therapy, one with complete 
and one with partial improvement; and the remaining dog was 
untreated but considered to have an initial partial improvement.
The median survival time for the total population (i.e. 
IRH-C + IRH-S, n=41) was 1482 (152 to 1825) days (Table 2). 
At the time of data collection, 21 dogs were still alive [median 
follow-up time 458 (49 to 2070) days] and 10 cases were lost to 
follow-up (eight at day 0, and two cases after 460 and 1228 days). 
The remaining 10 dogs were all euthanased with reasons cited 
in eight cases. Only one dog was euthanased due to persistent 
Table 1. Relevant clinical data and diagnostic abnormalities
All dogs Group IRH-C Group IRH-S
Patient data (n) 41 14 27
Age (median [range] years) 4.5 (0.3 to 13.3) 2.8 (0.3 to 9.1) 5.2 (0.4 to 13.3)
Weight (median [range] kg) 22.4 (7.2 to 74) 20.5 (12 to 72) 23.5 (7.2 to 74)
MN/ME/FN/FE (n) 15/9/11/6 3/2/4/5 12/7/7/1
Common breeds (n) Cocker spaniel (7) Cocker spaniel (3) Cocker spaniel (4)
Boxer (6) Boxer (2) Boxer (4)
Labrador (3) Springer spaniel (2) Labrador (2)
Haematology (n)† 37 12 25
PCV/HCT (median [range] %) 45 (21 to 59) 47 (24 to 52) 45 (21 to 59)
Prevalence of anaemia (%)‡ 22 33 16
Platelets (median [range]×109/L) 273 (122 to 543) 315 (169 to 436) 250 (122 to 543)
Biochemistry (n)† 36 12 24
Serum urea concentration (median [range] mmol/L) 5.6 (1.2 to 10.4) 5.4 (4.1 to 10.4) 5.8 (1.2 to 10.3)
Serum creatinine concentration (median [range] μmol/L) 91 (49 to 182) 72 (49 to 113) 92 (51 to 182)
Prevalence of renal/post-renal azotaemia (%)‡ 5 0 8
Urinalysis (n)† 36 10 26
Urine specific gravity 1.031 (1.010 to 1.050) 1.033 (1.028 to 1.045) 1.029 (1.010 to 1.045)
Urine protein: creatinine ratio 1.5 (0.2 to 17.4) 3.7 (0.5 to 8.7) 1.3 (0.2 to 17.4)
Prevalence of proteinuria (%)‡ 97 100 96
Urine RBC (/hpf) >50 in all dogs >50 in all dogs >50 in all dogs
Urine WBC (median [range]/hpf) <5 (<5 to 90) <5 (<5 to 90) <5 (<5 to 50)
Bacterial culture Negative in all dogs Negative in all dogs Negative in all dogs
Diagnostic imaging (n) 41 14 27
Prevalence of pyelectasia/ureteral dilation (%)‡ 24 29 22
Prevalence of ureteral/pelvic blood clots (%)‡ 15 14 15
Prevalence of urinary bladder blood clots (%)‡ 12 21 7
Prevalence of echogenic urinary bladder sediment (%)‡ 24 21 26
†Results were reported as unremarkable in remaining cases but unavailable for review
‡Prevalences based on population with data available for review
A. J. Kortum et al.
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haematuria, with all other cases related to other unrelated disease 
conditions or poor quality of life associated with old age. Over-
all, there was no significant difference in survival times of dogs 
treated with ACE-I/ARBs [1412 (152 to 1412) days] and those 
that were untreated [1825 (171 to 1825); P=0.81, Fig 2]. There 
was also no significant difference in survival times of dogs strati-
fied by response following treatment [complete resolution 834 
(182 to 834) days; partial improvement median survival time not 
reached (152); no improvement 1482 (1412 to 1482); response 
not recorded 1252 (273 to 1825) days; all P values >0.05].
Sub-analysis of group IRH-C
Of the 41 included dogs, 14 had visually confirmed haemor-
rhage from the UVJ (Group IRH-C). On sub-analysis of Group 
IRH-C, signalments, presenting signs, and clinicopathological 
and diagnostic imaging findings of IRH-C cases were similar to 
those for Group IRH-S and the total study population (Table 1). 
Cocker spaniels (three cases), boxers (two cases) and springer 
spaniels (two cases) were most commonly represented. Of the 
14 dogs, eight received benazepril [0.41 mg/kg/24 hours (0.21 
to 0.60)] and one received enalapril (0.78 mg/kg/24 hours), with 
treatment continued indefinitely in two, and discontinued after a 
median of 5.0 months (0.75 to 15) in the remaining seven dogs. 
The remaining five of 14 received no specific treatment.
Where outcome could be ascertained, complete resolution of 
haematuria was documented in three of seven (43%) ACEi/ARB-
treated cases, with partial improvement in two of seven (29%) and 
no improvement in two of seven (29%) (Fig 1). Only one dog, 
with initial partial improvement, was subsequently represented 
with haematuria. Of the five untreated dogs, response could be 
determined in only one which displayed no improvement.
Survival information was available for nine cases of which 
seven were still alive at the time of data collection with a median 
follow-up time of 543 (122 to 1846) days (Table 2). Of the 
two dogs which died, one achieved a complete response follow-
ing ACEi treatment but was euthanased after 834 days due to a 
subsequent diagnosis of multicentric lymphoma. The other case 
received no specific treatment and continued to have recurrent 
episodes of gross haematuria but was only ultimately euthanased 
after 1482 days as a consequence of acute-onset dyspnoea. There 
was no significant difference in survival between ACEi/ARB and 
untreated dogs (P=0.81, Fig 3, Table 2), or in survival times of 
dogs stratified by response following treatment (P > 0.05 for all 
comparisons, Table 2).
Sub-analysis of group IRH-S
Of the 41 included dogs, 27 were diagnosed based on the exclusion 
of other aetiologies (Group IRH-S). Signalments, presenting signs, 
and clinicopathological and diagnostic imaging findings of IRH-S 
cases were also similar to those for Group IRH-C and the total 
study population (Table 1) with cocker spaniels (four cases), boxers 
(four cases) and Labrador retrievers (two cases) most commonly 
represented. Fifteen dogs received benazepril [0.46 mg/kg/24 hours 
(0.19 to 0.82)], one of which was subsequently treated with telmis-
artan (1 mg/kg/24 hours), and one received enalapril (0.40 mg/
kg/24 hours). Treatment was continued indefinitely in five cases 
ACEi and ARBs in idiopathic renal haematuria
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and discontinued after a median of 9.5 months (0.75 to 52) in the 
remaining eight dogs where this information was recorded. The 
remaining 12 cases received no specific treatment.
Where outcome could be determined, complete resolution 
of haematuria was documented in five of 12 (42%) ACEi/ARB-
treated cases, partial improvement in three of 12 (25%), and no 
improvement in four of 12 (33%) (Fig 1). Follow-up was avail-
able for only one untreated dog which was considered to have 
had partial improvement. Relapse was reported in only this case 
and in one other dog which had previously experienced complete 
resolution of haematuria following enalapril therapy.
Median survival time for Group IRH-S was 1412 (152 to 
1825) days (Table 2). Fourteen dogs were still alive at the time 
of data collection [median follow-up time 445 (49 to 2070) 
days] and five cases were lost to follow-up (4 at day 0, and 1 
after 1228 days). The remaining eight dogs were all euthanased 
with only one as a consequence of persistent haematuria. Sur-
vival times were not significantly different irrespective of treat-
ment (P=0.75, Fig 4, Table 2), or response following treatment 
(P > 0.05 for all comparisons, Table 2).
DISCUSSION
In both Group IRH-C and Group IRH-S in this study, dogs 
diagnosed with IRH had long survival times irrespective of treat-
FIG 2. Kaplan–Meier survival analysis of the total study population (i.e. IRH-C and IRH-S groups combined), stratified by treatment (n=41). Survival 
times were compared between groups using the log rank test. Dogs that were alive or lost to follow up at the time of data collection were censored 
from the analysis (n=31). Median survival times were not significantly different between ACEi/ARB and untreated dogs (1412 days versus 1825 days, 
respectively; P=0.811)
FIG 3. Kaplan–Meier survival analysis of dogs in Group IRH-C stratified by treatment (n=14). Survival times were compared between groups using the 
log rank test. Dogs that were alive or lost to follow up at the time of data collection were censored from the analysis (n=12). Median survival times 
were not significantly different between ACEi/ARB and untreated dogs (834 days versus 1842 days, respectively; P=0.808)
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FIG 4. Kaplan–Meier survival analysis of dogs in Group IRH-S stratified by treatment (n=27). Survival times were compared between groups using the 
log rank test. Dogs that were alive or lost to follow up at the time of data collection were censored from the analysis (n=19). Median survival times 
were not significantly different between ACEi/ARB and untreated dogs (1412 days versus 1852 days, respectively; P=0.750)
ment and were often euthanased for reasons unrelated to IRH or 
progression of renal disease. Furthermore, longitudinal follow-up 
of these cases suggested that the development of anaemia or renal 
azotaemia were rare occurrences, even in cases with persistent 
haematuria. Many ACEi/ARB-treated dogs had either complete 
resolution of both gross and microscopic haematuria [eight of 
19 (42%) in the overall population or three of seven (43%) in 
Group IRH-C] or partial improvement [five of 19 (26%) in the 
overall population or three of seven (29%) in Group IRH-C] 
on reassessment. Conversely, haematuria persisted in both of the 
untreated dogs with ascertainable outcome; however, the partial 
improvement in one of these cases (Group IRH-S) raises the pos-
sibility that spontaneous improvement may also occur in a subset 
of dogs.
Similar to previous reports, dogs in this study were generally 
young to middle aged (median 4.5 years), otherwise healthy, and 
typically presented following the development of gross haema-
turia. Concurrent dysuria, attributed to voiding of blood clots 
or obstructive uropathy, also occurred in minority of patients, 
as previously described (Stone et al. 1983, Hitt et al. 1985, Holt 
et al. 1987, Mishina et al. 1997, Berent et al. 2013). However, 
the predilection for large breeds in the previously cited studies 
was not evident and, instead, cocker spaniels and boxers appeared 
commonly in our dataset (seven of 41 and six of 41 in the overall 
population; and three of 14 and two of 14 in Group IRH-C, 
respectively). Entire dogs also appeared subjectively overrepre-
sented; however, there was no clear sex predilection.
Azotaemia was relatively uncommon in our population at 
the time of diagnosis, which also mirrors the previous litera-
ture (Stone et al. 1983, Mishina et al. 1997, Berent et al. 2013, 
Di Cicco et al. 2013, Adelman et al. 2017). Unlike in previous 
reports where anaemia has been reported in up to 50% of patients 
(Stone et al. 1983, Holt et al. 1987, Di Cicco et al. 2013, Berent 
& Weisse 2014), anaemia was relatively uncommon in this study, 
occurring in only eight of 41 (20%) dogs at initial presentation 
[four of 14 (29%) of those in Group IRH-C], and generally mild 
to moderate in severity. The factors underlying these differences 
are not clear but may include a lesser severity of disease or dura-
tion of haemorrhage, different underlying aetiologies, individual 
differences in regenerative capacity or potentially overestimation 
of this complication in previous small case series. Nonetheless, 
despite the lower incidence and severity of anaemia, the pres-
ence of concurrent hypochromia and microcytosis in two dogs 
with non-regeneration, albeit without serum iron quantification, 
supports previous suggestions that iron-deficiency may occur as 
a consequence of chronic renal haemorrhage (Stone et al. 1983, 
Holt et al. 1987, Hawthorne et al. 1998, Berent & Weisse 2014).
Proteinuria was a common abnormality, occurring in the 
majority of dogs. Although this abnormality is often attributed 
to blood-derived proteins and consequently disregarded in hae-
maturic patients, previous studies have suggested that UPC is 
minimally affected by microscopic haematuria and, although it 
may be increased by gross haematuria, the impact of this is poorly 
defined and often overestimated (Vaden et al. 2004, Jillings et al. 
2019). In this study, it is interesting to note that the magnitude of 
proteinuria was highly variable, with UPCs ranging from 0.2 to 
17, and subjectively not obviously related to the severity of hae-
maturia. Although the contribution of blood-derived proteins is 
difficult to quantify and likely to have impacted on these results, 
the possibility of other contributing factors, such as glomerular 
protein loss, cannot be excluded. In humans, glomerular aeti-
ologies of haematuria (e.g. IgA nephropathy, Alport syndrome, 
and thin basement membrane disease) are common and may be 
distinguished by evaluation of urinary erythrocyte morphology, 
urine albumin:creatinine ratio and histopathology (Birch et al. 
1983, Tapp et al. 1986, Ohisa et al. 2007, Kelly et al. 2009, Yuste 
et al. 2015, Bolenz et al. 2018). In dogs, however, given the dif-
ficulties in interpreting proteinuria in cases with gross haematu-
ria, and that erythrocyte morphology and renal histopathology 
are infrequently evaluated, differentiation between glomerular 
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and non-glomerular aetiologies of renal haematuria is challeng-
ing. Evaluation of electrophoretic urine protein banding patterns 
have been shown to be useful for the detection of glomerular 
and tubulointerstitial damage in dogs with proteinuric chronic 
kidney disease; however, haematuria may confound interpreta-
tion and its use in IRH therefore requires further investigation 
(Hokamp et al. 2018).
Diagnostic imaging findings such as pyelectasia and echogenic 
urinary bladder sediment were relatively common findings, as 
also reported in previous canine cases (Stone et al. 1983, Holt 
et al. 1987, Berent et al. 2013). In addition, ureteral and blad-
der blood clots were documented in several cases which, despite 
the low incidence of azotaemia in this population, highlights 
a potential risk of urinary tract obstruction in patients with 
IRH. Cystoscopic findings were also similar to those previously 
described with bilateral haemorrhage occurring at a similar fre-
quency in this study (three of 14 cases) to that previously reported 
(cumulatively 21% of cases), and highlighting the importance 
of renal-sparing treatments (Stone et al. 1983; Holt et al. 1987; 
Hawthorne et al. 1998; Berent & Weisse 2014). However, 
whereas previous reports have described the left kidney as being 
predominantly affected, no obvious predisposition was appar-
ent in this study (Stone et al. 1983, Hitt et al. 1985, Holt et al. 
1987, Jennings et al. 1992, Mishina et al. 1997, Hawthorne et al. 
1998, Berent et al. 2013).
Overall, responses following ACEi/ARB treatment compared 
favourably to a previous study evaluating sclerotherapy with 
povidone iodine and silver nitrate for IRH which documented 
complete and partial responses in four of six (67%) and two of 
six (33%) dogs, respectively (Berent et al. 2013). In the current 
study population, complete resolution of haematuria was docu-
mented eight of 19 (42%) dogs, with partial improvement in a 
further five of 19 (26%). Although it could be argued that this 
may reflect the inclusion of cases with other aetiologies in Group 
IRH-S, complete and partial improvements were also docu-
mented in a similar proportion of cases in Group IRH-C (43 and 
29%, respectively). Furthermore, few dogs were subsequently 
represented for haematuria and recurrence rates were similar 
regardless of whether the whole study population or only Group 
IRH-C are evaluated (21 and 14%, respectively). Although 
meaningful statistical comparisons were precluded by the small 
number of cases in the present study and a cause-and-effect rela-
tionship cannot be established from this preliminary data, the 
complete resolution of haematuria in 42% of ACEi/ARB-treated 
cases suggests that these medical therapies are deserving of further 
investigation. Nonetheless, it should be noted that, whilst neither 
had resolution of haematuria, one (Group IRH-S) of the two 
untreated cases with ascertainable outcome was reported to have 
had partial improvement. Although this may be attributed to the 
subjective assessment of gross haematuria, or incorrect diagnosis, 
it is possible that spontaneous improvement of IRH may also 
occur and this eventuality should consequently be considered in 
any future studies evaluating treatment response.
Perhaps contrary to perceived opinion, the prognosis for dogs 
in our study was generally excellent with median survival times 
exceeding 1400 days, regardless of the severity of initial present-
ing signs, institution of ACEi/ARB therapy, or response to treat-
ment. The cause of death or euthanasia was usually not recorded, 
therefore all-cause mortality (rather than mortality associated 
with IRH) was reported in the present study, which is likely to be 
affected by other factors. In support of this, many patients were 
still alive at the study end-point and, of those that were eutha-
nased, motivations mostly pertained to unrelated conditions or 
poor quality of life relating to old age. The finding that many 
dogs, including cases with persistent haematuria (often docu-
mented on numerous occasions during follow-up), survived or 
were still alive several years after diagnosis was an unexpected 
finding and presumably indicates either that the condition has 
a waxing/waning or milder course in some dogs, or that their 
owners learn to tolerate the haematuria once underlying life-
threatening or serious pathologies have been ruled out. Nonethe-
less, one dog was euthanased due to persistent haematuria and 
hypochromic anaemia, and poor response to treatment, serving 
as a reminder that IRH may still be associated with severe and 
life-limiting clinical signs.
This study has several important limitations. Firstly, despite 
aiming to maximise case numbers by inclusion of dogs from four 
referral centres and sub-populations with both confirmed and 
suspected IRH, this study remains limited by the rarity of the 
disease. Furthermore, despite thorough collation of all available 
medical records and contacting referring veterinary practices, 
follow-up information was unavailable or incomplete for a large 
number of cases. Consequently, the lack of statistical power of 
the study precluded further statistical analysis of the association 
between treatment and response, or patient characteristics and 
clinical parameters that were associated with outcome.
Secondly, inherent to its retrospective nature, diagnostic inves-
tigations and treatment decisions were not standardised and 
clinical data was not always available for review, especially in his-
toric cases. Consequently, complete data could not be obtained 
in all cases, particularly regarding blood pressure and coagulation 
assessment, and motivations for euthanasia. Although diagnostic 
imaging including abdominal ultrasound was performed in all 
cases, radiography was only performed adjunctively in 25 dogs 
and small radiopaque uroliths, despite being considered unlikely, 
could have gone undetected. In addition, given that medical 
record searches were performed independently in each institution 
and search terms and methods were not standardised, the possibil-
ity of selection bias cannot be excluded. Furthermore, untreated 
cases tended to be older (2001 to 2016) than those treated with 
ACEi/ARBs (2012 to 2018) and some dogs also received other 
treatments in addition to ACEi or ARBs which, although gener-
ally considered unlikely, may have had a confounding effect on 
outcome. Conversely, other medical treatments which have been 
anecdotally suggested to be beneficial in IRH, such as aminoca-
proic acid or the Chinese herbal remedy, Yunnan Baiyao, were not 
administered to dogs in this study. Tranexamic acid, an antifibri-
nolytic agent, was coadministered with ACEi in two cases; how-
ever, haematuria resolved in neither dog. In addition, the timing 
and extent of follow-up monitoring were variable; many cases 
had only one follow-up urinalysis performed and, despite the low 
representation rate, it is therefore possible that any improvement 
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may have been transient. The duration of haematuria may also 
have been influenced by the gradual breakdown of blood clots; 
however, repeat imaging was infrequently performed. Conse-
quently, larger randomised, blinded, placebo-controlled prospec-
tive studies would be required to evaluate the efficacy of ACEi/
ARB for the treatment of IRH. In addition, additional studies 
are indicated to clarify the pathogenesis of canine IRH and deter-
mine if, and at what frequency, glomerular and non-glomerular 
aetiologies occur in this species.
Finally, despite the similarities in patient characteristics, diag-
nostic abnormalities and outcomes between IRH-C and IRH-S 
sub-populations, our decision to include dogs without confirmed 
renal haemorrhage (group IRH-S) may have inadvertently led to 
the inclusion of other aetiologies. For example, a recent case series 
suggests that macroscopic haematuria without signs of lower uri-
nary tract disease may rarely occur due to lower urinary tract 
lesions which may not be apparent without cystourethroscopic 
examination (Himelman et al. 2019). However, diagnostic inves-
tigation in clinical practice is often influenced by financial factors 
and client motivations, and the availability and clinical experience 
of cystoscopy. Applying rigorous inclusion criteria would there-
fore likely to have resulted in a very small study population and 
risked exclusion of valuable data, such as that from historic cases 
and male patients which may have been less likely to have under-
gone cystoscopy. Consequently, we considered the inclusion of a 
larger dataset to be valuable in characterising this rare condition 
but evaluated and presented data from group IRH-C separately 
in an attempt to mitigate any limitations relating to case inclu-
sion. Similarly, due to the subjectivity associated with evaluating 
change in gross haematuria, cases with partial improvement (i.e. 
those with reduction in the severity of gross haematuria but per-
sistence of microscopic haematuria) were evaluated separately to 
those with complete remission or no improvement.
In conclusion, in both Group IRH-C and Group IRH-S 
in this study, dogs with IRH generally had long survival times 
and excellent prognoses, irrespective of treatment with ACEi or 
ARBs, or progression of haematuria. Although complications 
such as anaemia and euthanasia relating to intractable clinical 
signs occurred in a small proportion of cases, these outcomes 
were infrequent in this study population. Improvement or reso-
lution of clinical signs occurred in many ACEi/ARB treated dogs 
but also occurred in untreated cases. Further studies are therefore 
required to evaluate the relationship between treatment and out-
come, and to elucidate the pathogenesis of canine IRH.
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